NEUP (Neuphoria Therapeutics) Days Payable: 0.00 (As of Mar. 2026)

What is Neuphoria Therapeutics Days Payable?

Neuphoria Therapeutics NEUP +5.18% 32 Days Payable is 0.00 as of Mar. 2026. GuruFocus rates NEUP with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 707 Biotechnology companies, Neuphoria Therapeutics ranks worse than 141442.57% on this metric.

Neuphoria Therapeutics's average Accounts Payable for the three months ended in Mar. 2026 was $0.57 Mil. Neuphoria Therapeutics's Cost of Goods Sold for the three months ended in Mar. 2026 was $0.00 Mil.

The historical rank and industry rank for Neuphoria Therapeutics's Days Payable or its related term are showing as below:

NEUP's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 113.76
* Ranked among companies with meaningful Days Payable only.

Neuphoria Therapeutics's Days Payable stayed the same from Mar. 2025 (0.00) to Mar. 2026 (0.00). stayed the same

Neuphoria Therapeutics Days Payable Related Terms

Neuphoria Therapeutics Days Payable Historical Data

* Premium members only.

The historical data trend for Neuphoria Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neuphoria Therapeutics Days Payable Chart

Neuphoria Therapeutics Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Jun25

Days Payable

Get a 7-Day Free Trial

0.00

Neuphoria Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Days Payable	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

NEUP vs CRVO, IGC, SNSE: Days Payable Comparison

For the Biotechnology subindustry, Neuphoria Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neuphoria Therapeutics Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neuphoria Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Neuphoria Therapeutics's Days Payable falls into.

Save Embed

32GF Score

Neuphoria Therapeutics Inc NEUP

Days Payable is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Neuphoria Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Neuphoria Therapeutics's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as

	Days Payable (A: Jun. 2025 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Jun. 2024 )	+	Accounts Payable (A: Jun. 2025 ))	/	count )	/	Cost of Goods Sold (A: Jun. 2025 )	*	Days in Period
=	( (2.244	+	1.154)	/	2 )	/	0	*	365
=	1.699					/	0	*	365
=	N/A

Neuphoria Therapeutics's Days Payable for the quarter that ended in Mar. 2026 is calculated as:

	Days Payable (Q: Mar. 2026 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2025 )	+	Accounts Payable (Q: Mar. 2026 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2026 )	*	Days in Period
=	( (0.521	+	0.627)	/	2 )	/	0	*	365 / 4
=	0.574					/	0	*	365 / 4
=	N/A

Frequently Asked Questions Learn more about Days Payable →

What does a Days Payable of 0.00 mean?

Neuphoria Therapeutics (NEUP) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Neuphoria Therapeutics and its competitors. According to the industry distribution chart, Neuphoria Therapeutics ranks #999999 out of 707 companies in the Biotechnology industry.

Is Neuphoria Therapeutics' Days Payable too high?

Neuphoria Therapeutics' current Days Payable is 0.00. Based on the distribution chart, Neuphoria Therapeutics ranks #999999 out of 707 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Neuphoria Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.

How does Neuphoria Therapeutics' Days Payable compare to CRVO and IGC?

According to the Biotechnology industry distribution chart, Neuphoria Therapeutics ranks #999999 out of 707 companies for Days Payable. This places Neuphoria Therapeutics in the lower half of its industry. The industry median Days Payable is 113.76. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Days Payable for a Biotechnology company?

The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Days Payable mean?

A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Neuphoria Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neuphoria Therapeutics's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Neuphoria Therapeutics stock overvalued right now?

Neuphoria Therapeutics (NEUP) has a current Days Payable of 0.00. The current Days Payable is 0.00. Neuphoria Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Days Payable calculated?

Days Payable is calculated from a company's financial statements. For Neuphoria Therapeutics (NEUP), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neuphoria Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies CRVO IGC SNSE CELU DYAI KYNB SNTI NRSN SER LSTA VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Address 100 Summit Drive, Burlington, MA, USA, 01803

Website https://www.neuphoriatx.com

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

32GF Score

Get the complete analysis for NEUP

Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.53

Price

View NEUP Analysis

See Days Payable data for all stocks →